(Sharecast News) - Shares in Moderna tumbled 11% in pre-market trading on Thursday, after the US biotech detailed plans to cut its research budget by more than $1bn.
The Nasdaq-listed firm said it would focus on ten product approvals through 2027, including a next-generation Covid vaccine and combined 'flu and Covid...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE